FDA-approved
Hormones & metabolism
Dulaglutide
Evidence
FDA approved
Class
GLP-1 receptor agonist (Fc fusion)
KEY TAKEAWAY
Dulaglutide is a GLP-1 analog attached to part of a human antibody so that it lasts about a week. It is sold as Trulicity. The FDA approved dulaglutide (Trulicity) in 2014 for type 2 diabetes, and later for lowering the risk of major cardiovascular events in adults with type 2 diabetes.
Written by the Veylo editorial team · Updated
November 2026
What it is
GLP-1 receptor agonist (Fc fusion)
Approved for
Type 2 diabetes and cardiovascular risk reduction
Key fact
The FDA approved dulaglutide (Trulicity) in 2014 for type 2 diabetes, and later for lowering the risk of major cardiovascular events in adults with type 2 diabetes.
Route
Weekly subcutaneous injection
Evidence strength
FDA approved
Dulaglutide is a GLP-1 analog attached to part of a human antibody so that it lasts about a week. It is sold as Trulicity.
It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and reduces appetite.
The FDA approved dulaglutide (Trulicity) in 2014 for type 2 diabetes, and later for lowering the risk of major cardiovascular events in adults with type 2 diabetes.
Type 2 diabetes and cardiovascular risk reduction.
Nausea, vomiting and diarrhea are most common. The label carries a boxed warning about thyroid C-cell tumors seen in rodents.
U.S. FDA prescribing information for Dulaglutide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.